LICENSING & ACQUISITIONS

We seek to acquire products and technologies, including drugs, devices, and drug-delivery systems, at any stage of their development. Our expertise in preclinical and clinical development through product commercialization makes us an ideal partner for any company with assets focused on critical care conditions.

We also are committed to enabling the broader industry access to licensing support. If you are interested in licensing your product or technology, or expanding your product’s presence in the hospital, we welcome hearing from you.

Our specific areas of interest focus upon:

• Neonatal ICU indications
• Sepsis/shock/severe shock
• Acute, severe respiratory conditions, such as acute respiratory distress syndrome and acute lung injury
• Renal disorders, such as acute kidney injury and contrast-induced nephropathy
• Complications of cirrhosis
• Transplant
• Acute exacerbation of chronic diseases, such as congestive heart failure, Cystic Fibrosis, idiopathic pulmonary fibrosis and status asthmaticus
• Acute pancreatitis
• Surgical supportive/preventative therapies, such as CABG-ischemia reperfusion injury, vascular stenosis, peri- and post-operative glycemic control, and surgical bleeding

Contacts

For pharmaceutical and biotech companies interested in product licensing and acquisitions, please contact us at the email address below. If you are not inquiring about product licensing or acquisitions, please visit our Contact Us page so that your inquiry can be directed to the appropriate department.

To discuss potential licensing or acquisition opportunities with Ikaria, please contact:

BusinessDevelopment@ikaria.com

Corporate Headquarters
Ikaria
6 State Route 173
Clinton, NJ 08809

Tel: 908-238-6600, Fax: 908-238-6633